

Organovo Celebrates a Positive 2014 Reception of its exVive3D™ Human Liver Tissue Product

December 15, 2014 2:40 PM ET

SAN DIEGO, Dec. 15, 2014 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today celebrated continued positive reception by the industry and collaborators of its exVive3D™ Human Liver Tissue. The product, which was made widely available in full commercial release on November 18, has been recognized as groundbreaking in the field, resulting in several awards for innovation.

Most recently, on December 4, Organovo's exVive3D™ Human Liver Tissue was selected by a panel of industry judges as a **CONNECT 2014 Most Innovative Product**. CONNECT is a San Diego innovation organization, with membership from over 120 firms and universities, that catalyzes the creation of innovative technology and life sciences products in San Diego. The exVive3D™ Human Liver was selected as the winner from a highly innovative set of competitive research tools and diagnostic products.

Also this month, the exVive3D™ Human Liver Tissue was selected by a separate panel of judges from industry and academia as one of the **Top 10 Innovations of 2014 by The Scientist magazine**, a widely read and well respected news outlet for life science researchers.

Earlier this year Organovo's liver tissue was also named a Silver award winner in the life science space at the **2014 Edison Awards** and the Company was named a **2015 Technology Pioneer by the World Economic Forum**.

"Organovo's first-in-class tissue has been very well received by the scientific community," commented Organovo Chief Executive Officer Keith Murphy. "Our current data provides ample evidence for customers to engage in our commercial research services, and we have been honored by a number of awards acknowledging the innovative nature of our product. We look forward to continuing to expand the impact and uptake of the exVive3D™ Human Liver Tissue, along with extending our offering with other equally innovative tissue types."

About Organovo Holdings, Inc.

Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners. Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The company recently launched its initial product of the planned exVive3D™ portfolio offering, a 3D Human Liver Tissue for use in Toxicology and other preclinical drug testing. Additional products, including a 3D Kidney Model, are in development with anticipated release for use in the latter half of calendar year 2016. The company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the market acceptance of the Company's products; and the Company's business, research, product development, regulatory approval, marketing and distribution

plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our annual report on Form 10-K filed with the SEC on June 10, 2014 and its report on Form 10-Q filed with the SEC on November 7, 2014, as well as our other filings with the SEC. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/organovo-celebrates-a-positive-2014-reception-of-its-exvive3dtm-human-liver-tissue-product-300009373.html>

SOURCE Organovo Holdings, Inc.

Barry Michaels, Chief Financial Officer, 858-224-1000, ext. 3, IR@organovo.com, or Gerry Amato, Amato and Partners, LLC, Investor Relations, gerald@amatoandpartners.com; Media Contact, Mike Renard, EVP, Commercial Operations, 858-224-1006, mrenard@organovo.com